Related Experiment Video
Updated: May 31, 2026

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats
Published on: September 27, 2024
Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options
Juraj Payer1, Kristina Brazdilova, Peter Jackuliak
15th Department of Internal Medicine, Medical Faculty of Comenius University and Faculty Hospital Bratislava, Bratislava, Slovakia.
Abstract:
An excess amount of glucocorticoids represents the primary and most frequent etiological factor influencing secondary osteoporosis. Patients receiving glucocorticoids, but also those with the endogenous form of hypercorticism, are at high risk for the loss of bone density, with the subsequent occurrence of pathological fractures. In this review, we summarize the currently available methods of prevention and the treatment of glucocorticoid-induced osteoporosis. We also include a proposal for both a prophylactic and therapeutic approach that takes into account the risk factors typical for long-term users of glucocorticoids.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
COPD: Management Using Bronchodilators and Corticosteroids
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Osteoclasts in Bone Remodeling
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...